Predictive Biosciences and Affinity Life Sciences Collaborate in the Development of Unique Biomarker Assays
Lexington, MA, February 17, 2011 --(PR.com)-- Predictive Biosciences, a recognized leader in novel molecular diagnostics and Affinity Life Sciences, specialists in biomarker assay development and cGMP compliant production, are working together on the development of specific biomarker assays for use in clinical studies.
This collaboration provides Predictive with additional support services by utilizing Affinity’s expertise in biomarker immunoassay development. Predictive Biosciences, having a well established R&D and CLIA testing facilities, will expand its cancer diagnostic menu with support from Affinity.
“We are excited about the work we are doing to support Predictive’s evolution of oncology testing. They are an outstanding organization with a significant product pipeline and are well prepared for growth,” said Tod Gavron, President of Affinity.
About Affinity Life Sciences, Inc.
Affinity Life Sciences is a Contract Research and Manufacturing Organization providing R&D, testing, manufacturing, and commercialization services for the diagnostic and pharmaceutical industries. Affinity specializes in biomarker and immunochemistry assay design, development, and commercialization for research use or under cGMP conditions. Visit Affinity at www.affinitylifesciences.com to learn more about Affinity’s custom services.
About Predictive Biosciences, Inc.
Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays and an urology-focused provider of anatomic pathology laboratory products and services. Leveraging a portfolio of patented biomarkers and clinical approaches, the company is building a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. For additional information, please visit www.predictivebiosci.com.
For more information:
Tod Gavron
Affinity Life Sciences, Inc.
+1(603) 249-1644 ext.102
tgavron@afflif.com
Sharon Martin
Predictive Biosciences
+1 (781) 402-1780 ext. 246
mgirardi@predictivebiosci.com
###
This collaboration provides Predictive with additional support services by utilizing Affinity’s expertise in biomarker immunoassay development. Predictive Biosciences, having a well established R&D and CLIA testing facilities, will expand its cancer diagnostic menu with support from Affinity.
“We are excited about the work we are doing to support Predictive’s evolution of oncology testing. They are an outstanding organization with a significant product pipeline and are well prepared for growth,” said Tod Gavron, President of Affinity.
About Affinity Life Sciences, Inc.
Affinity Life Sciences is a Contract Research and Manufacturing Organization providing R&D, testing, manufacturing, and commercialization services for the diagnostic and pharmaceutical industries. Affinity specializes in biomarker and immunochemistry assay design, development, and commercialization for research use or under cGMP conditions. Visit Affinity at www.affinitylifesciences.com to learn more about Affinity’s custom services.
About Predictive Biosciences, Inc.
Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays and an urology-focused provider of anatomic pathology laboratory products and services. Leveraging a portfolio of patented biomarkers and clinical approaches, the company is building a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. For additional information, please visit www.predictivebiosci.com.
For more information:
Tod Gavron
Affinity Life Sciences, Inc.
+1(603) 249-1644 ext.102
tgavron@afflif.com
Sharon Martin
Predictive Biosciences
+1 (781) 402-1780 ext. 246
mgirardi@predictivebiosci.com
###
Contact
Affinity Life Sciences
Tod Gavron
603-249-1644
www.affinitylifesciences.com
Tod Gavron
603-249-1644
www.affinitylifesciences.com
Contact
Categories